PNTG Stock Forecast & Price Target

Pennant Gr is benefiting from strong execution in both organic growth and acquisitions, with same-store Medicare home health admissions up 13.6% and hospice ADC up 10.8%, while senior living occupancy improved to 81.6% and RevPOR rose 5.5%. Integration of the former UNH/AMED assets is tracking ahead of schedule, volume is holding above expectations through brand and leadership changes, and margins are already improving as EMR and clinical best practices are implemented. The outlook is further supported by a more favorable reimbursement backdrop, including a proposed 2.4% home health increase for 2027 and 2.3% hospice rate increase, alongside raised 2026 guidance for revenue, adjusted EBITDA, and adjusted EPS.

Pennant Gr is facing a fragile operating setup because integration headwinds in transitioning assets could force management to pause incremental M&A, undermining a key growth lever in a business built on rapid expansion. The downside case also assumes Home Health and Hospice topline momentum plateaus while labor pressures rise, which would compress margins and leave FY27E EBITDAR 5% below current estimates. Its heavy reliance on Medicare-funded reimbursement, exposure to compliance risk in a fragmented multi-state workforce, and senior housing occupancy pressure from supply headwinds all reinforce a bearish fundamental outlook.